New drugs targeting the cardiac ultra-rapid delayed-rectifier current (IKur): Rationale, pharmacology and evidence for potential therapeutic value

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 2, 2008, Pages 105-120

  Ford, John W ^a   Milnes, James T ^a  

^a Xention Limited   (United Kingdom)

Author keywords

Arrhythmia; Atrial fibrillation; Atrial flutter; Cardiac; Heart; IKur; Kv1.5; Ultra rapid delayed rectifier

Indexed keywords

1 N AMINO 2 IMIDAZOLIDONONE DERIVATIVE; 1,2,3 TRIAZOLE DERIVATIVE; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 OXO 1,3,8 TRIAZA SPIRO (4,5) DECANE DERIVATIVE; ANTHRANILIC ACID DERIVATIVE; AVE 1231; AVE 3295; BENZOPYRAN DERIVATIVE; BISARYL DERIVATIVE; C 9356; CARBAMIC ACID DERIVATIVE; DELAYED RECTIFIER POTASSIUM CHANNEL; DIISOPROPYL 2 PYRIDINE ACETAMIDE DERIVATIVE; ICAGEN 4; IMIDAZO DERIVATIVE; INDAN DERIVATIVE; ISOTHIAZOLIDINE 1,1 DIOXIDE DERIVATIVE; LIDOCAINE; PIPERIDINE 2 ONE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; PYRROLIDIN 2 ONE DERIVATIVE; RANOLAZINE; S 20951; S 9947; SEMICARBAZONE DERIVATIVE; SO 100176; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT; ANTIARRHYTHMIC AGENT;

ANTIARRHYTHMIC ACTIVITY; CARDIOSELECTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; KV1.5 POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKERS;

EID: 56149117926     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181719b0c     Document Type: Review

References (142)

1. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet need. Am Heart J. 2006;151:771-778.
2. DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92:1064-1070.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114:119-125.
4. Ohsawa M, Okayama A, Sakata K, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: An analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol. 2005;15:194-196.
5. Fleetwood A. Stakeholder insight atrial fibrillation. Datamonitor. 2006. DMHC2176.
6. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147:121-126.
7. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
8. Steinberg JS. Atrial fibrillation: an emerging epidemic? Heart. 2004;90: 239-240.
9. Hohnloser SH, Capucci A, Fain E, et al. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J. 2006;152:442-447.
10. Nattel S. New ideas about atrial fibrillation 50 years on. Nature.2002; 415:219-226.
11. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhyth-mic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-728.
12. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhyth-mics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;CD005049.
13. Vassallo P, Trohman RG. Prescribing amiodarone: An evidence-based review of clinical indications. JAMA. 2007;298:1312-1322.
14. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008 Jan 7; doi: 10.1016/j.ijcard. 2007.11.006. [Epub ahead of print].
15. Camm AJ, Savelieva I. Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm. 2004;1: 244-246.
16. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5:1034-1049.
17. + current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73: 1061-1076.
18. Fedida D, Wible B, Wang Z, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res. 1993;73:210-216.
19. Feng J, Wible B, Li GR, et al. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res. 1997;80: 572-579.
20. Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol. 1996;491:31-50.
21. Li GR, Feng J, Yue L, et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 1996;78:689-696.
22. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiov Res. 2002;54:347-360.
23. Kur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006;114:1234-1242.
24. 2+-exchange. Cardiovasc Res. 2007;73:37-47.
25. Wang Z, Fermini B, Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther. 1995;272: 184-196.
26. Fedida D, Eldstrom J, Hesketh JC, et al. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes. Circ Res. 2003;93:744-751.
27. Eldstrom J, Van Wagoner DR, Moore ED, et al. Localization of Kv1.5 channels in rat and canine myocyte sarcolemma. FEBS Lett. 2006;580: 6039-6046.
28. Yue L, Feng J, Li GR, et al. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol. 1996;270:H2157-H2168.
29. Yue L, Feng J, Li GR, et al. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol. 1996;496:647-662.
30. Ehrlich JR, Hoche C, Coutu P, et al. Properties of a time-dependent potassium current in pig atrium - Evidence for a role of Kv1.5 in repolarization. J Pharmacol Exp Ther. 2006;319:898-906.
31. Boyle WA, Nerbonne JM. A novel type of depolarization-activated K+ current in isolated adult rat atrial myocytes. Am J Physiol. 1991;260: H1236-H1247.
32. + channel (Kv1.5) cloned from rabbit heart and facilitation of inactivation of the delayed rectifier current by the rat β-subunit. FEBS Lett. 1995;372:20-24.
33. Van Der Velden HMW, van der Zee L, Wijffels MC, et al. Atrial fibrillation in the goat induces changes in monophasic action potential and mRNA expression of ion channels involved in repolarization. J Cardiovasc Electrophysiol. 2000;11:1262-1269.
34. Kur blocker, ISQ-1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol. 2007;49: 236-245.
35. Dobrzynski H, Rothery SM, Marples DD, et al. Presence of the Kv1.5 K+ channel in the sinoatrial node. J Histochem Cytochem. 2000;48:769-780.
36. Sridhar A, da Cunha DNQ, Lacombe VA, et al. The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol. 2007;152: 870-879.
37. + channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006;317:1054-1063.
38. Sun X, Wang HS. Role of the transient outward current (Ito) in shaping canine ventricular action potential - A dynamic clamp study. J Physiol. 2005;564:411-419.
39. + channel subunit in the mouse heart. Circ Res. 1999; 85:1067-1076.
40. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev. 2005;85:1205-1253.
41. Schram G, Pourrier M, Melnyk P, et al. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res. 2002;90:939-950.
42. Km-blockade in vivo atrial electrical remodeling and antiarrhyth-mic drugs. J Cardiovasc Electrophysiol. 2007;18:1313-1320.
43. Kur channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, d, l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:482-487.
44. KACh class Ic drugs and beta blockers in pigs. Med Sci Monit. 2004;10:BR221-BR228.
45. Gögelein H, Brendel J, Steinmeyer K, et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:183-192.
46. Decher N, Kumar P, Gonzalez T, et al. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol. 2006;70:1204-1211.
47. Wettwer E, Hala O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation. 2004;110:2299-2306.
48. Lofberg L, Jacobson I, Carlsson L. Electrophysiological and antiar-rhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace. 2006;8:549-557.
49. +-channel-blocker AVE0118 in anesthetized pigs. Cardiov Res. 2003; 60:298-306.
50. Blaauw Y, Gögelein H, Tieleman RG, et al. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004;110:1717- 1724.
51. Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation. 1994;89:2509-2513.
52. Oros A, Volders PG, Beekman JD, et al. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block. Heart Rhythm. 2006;3:1339-1345.
53. Fish JM, Extramiana F, Antzelevitch C. AVE0118, an Ito and IKur blocker, suppresses vt/vf in an experimental model of the Brugada Syndrome. Circulation. 2004;110:Abstract 924.
54. Wirth KJ, Brendel J, Steinmeyer K, et al. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol. 2007;49:197-206.
55. Sanofi-Aventis Website. Sanofi-Aventis Investor Meeting New York: 22 March 2006. Available at http://www.sanofi-aventis.com/Images/ 060322-slides-NY-en-tcm23-12824.pdf. Accessed January 1, 2008.
56. Sanofi-Aventis Website. Sanofi-Aventis R&D Portfolio. Sept 2007. Available at http://en.sanofi-aventis.com/rd/portfolio/p-rd-portfolio- cardio.asp. Accessed January 14, 2008.
57. Bachmann A, Gutcher I, Kopp K, et al. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol. 2001;364: 472-478.
58. Strutz-Seebohm N, Gutcher I, Decher N, et al. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell Physiol Biochem. 2007;20:791-800.
59. Gögelein H, Brendel J, Bleich M, et al. Novel atrial K channel blockers AVE3295 and AVE1231 for prevention of recurrence of atrial fibrillation. Heart Rhythm. 2004;1:S103.
60. Peukert S, Brendel J, Pirard B, et al. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004;14:2823-2827.
61. Decher N, Pirard B, Bundis F, et al. Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem. 2004;279:394-400.
62. Brendel J, Englert HC, Peukert S, et al. Substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1, 1-dioxides, their use as Kv1.5 potassium channel blockers and pharmaceutical preparations comprising them. Sanofi Aventis, assignee. Patent WO/ 2006/136305. December 2006.
63. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
64. Beatch GN, Lin S-P, Hesketh C, et al. Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug. Circulation. 2003; 108:IV-85.
65. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-1457.
66. Fedida D. Vernakalant (RSD1235): A novel, atrial-selective antifibrilla-tory agent. Expert Opin Investigat Drugs. 2007;16:519-532.
67. Plouvier BMC, Fedida D, Beatch GN, et al. Imidazo compounds and use there of. Cardiome Pharma, assignee. Patent WO/2005/034837. April 2005.
68. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 2003;107:2037-2044.
69. Beaudoin S, Reed AD, Gross MF. Potassium channel inhibitors. Icagen Inc., assignee. Patent WO/2002/060874. August 2002.
70. Kur potassium channel. Expert Opin Therap Pat. 2007;17: 1443-1456.
71. Castle NA, Hollinshead SP, Hughes PF, et al. Potassium channel inhibitors. Icagen Inc., Eli Lilly and Company, assignees. Patent WO/ 1998/004521. February 1998.
72. Gross MF, Beaudoin S, Naughton-Smith G, et al. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel. Bioorg Med Chem Lett. 2007;17:2849-2853.
73. Gross MF, Beaudoin S, Reed AD; Potassium channel inhibitors. Icagen Inc., assignee. Patent WO/2001/046155. June 2001.
74. Lloyd J, Atwal KS, Finlay HJ, et al. Benzopyran sulfonamides as Kv1.5 potassium channel blockers. Bioorg Med Chem Lett. 2007;17:3271- 3275.
75. Beaudoin S, Gross MF, Reed AD, et al. Potassium channel inhibitors. Icagen Inc., assignee. Patent WO/2002/008183. January 2002.
76. Reed AD, Gross MF, Beaudoin S. Potassium channel inhibitors. Icagen Inc., assignee. Patent WO/2002/008191. January 2002.
77. Regan CP, Wallace AA, Cresswell HK, et al. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Ther. 2006;316: 727-732.
78. Kur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther. 2005;315:1362-1367.
79. Lynch JJ Jr, Salata JJ, Swanson RJ, et al. Methods of treating or preventing cardiac arrhythmia. Merck & Co., assignee. Patent WO/1998/ 018475. May 1998.
80. Lynch JJ Jr, Salata JJ, Swanson RJ, et al. Methods of treating or preventing cardiac arrhythmia. Merck & Co., assignee. Patent WO/1998/ 018476. May 1998.
81. Trotter BW, Nanda KK, Kett NR, et al. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J Med Chem. 2006;49:6954-6957.
82. Regan CP, Kiss L, Stump G, et al. Atrial antifibrillatory effects of structurally distinct IKur blockers ISQ-1 (3-[(Dimethylamino)methyl]-6-methoxy- 2-methyl-4-phenylisoquinolin-1(2H)-one) and TAEA (2-Phenyl-1,1-dipyridin-3-yl-2- pyrrolidin-1-yl-ethanol) in dogs with underlying heart failure. J Pharmacol Exp Ther. 2008;324:322-330.
83. Nanda KK, Nolt MB, Cato MJ, et al. Potent antagonists of the Kv1.5 potassium channel: Synthesis and evaluation of analogous N, N-diisopropyl-2- (pyridine-3-yl)acetamides. Bioorg Med Chem Lett. 2006;16:5897-5901.
84. Blass BE, Coburn K, Lee W, et al. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation. Bioorg Med Chem Lett. 2006;16:4629-4632.
85. Wu S, Fluxe A, Janusz JM, et al. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers. Bioorg Med Chem Lett. 2006;16:5859-5863.
86. Fluxe A, Wu S, Sheffer JB, et al. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers. Bioorg Med Chem Lett. 2006;16:5855-5858.
87. Wu S, Fluxe A, Sheffer J, et al. Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers. Bioorg Med Chem Lett. 2006;16: 6213-6218.
88. Janusz JM, Wu S, Fairweather NT, et al. Kv1.5 potassium channel inhibitors. Wyeth Corp., assignee. Patent WO/2007/149873. December 2007.
89. Janusz JM, Hodson SJ, Bosch GK, et al. Imidazole Kv1.5 potassium channel inhibitors. Wyeth Corp., assignee. Patent WO/2007/149874. December 2007.
90. Xention Ltd. XENTION INITIATES PHASE I STUDY-XEN-D0101 Enters Clinical Development for Atrial Fibrillation. September 2006. http:\\www.xention.com/ PDFs/Phase1.pdf. Accessed January 1, 2008.
91. Kmr/Kv1.5 blocker in dogs. Heart Rhythm. 2005;2:S180.
92. Km/Kv1.5 blocker in dogs with atrial tachycardia remodeling. Heart Rhythm. 2006;5:S183.
93. Grammer JB, Bosch RF, Kuhlkamp V, et al. Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J Cardiovasc Electrophysiol. 2000;11:626-633.
94. Workman AJ, Kane KA, Rankin AC. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res. 2001;52:226-235.
95. Bosch RF, Zeng X, Grammer JB, et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiov Res. 1999;44: 121-131.
96. Bosch RF, Nattel S. Cellular electrophysiology of atrial fibrillation. Cardiov Res. 2002;54:259-269.
97. Brendel J, Gerlach U, Stilz HU, et al. Indanyl-substituted benzenecar-boxamides, processes for their preparation, their use as a medicament, and pharmaceutical formulations containing them. Aventis Pharma GMBH, assignee. Patent US622 1866. April 2001.
98. Brendel J, Gerlach U, Stilz HU, et al. Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same. Aventis Pharma GMBH, assignee. Patent WO/2001/000573. January 2001.
99. Peukert S, Brendel J, Hemmerle H, et al. Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds. Aventis Pharma GMBH, assignee. Patent WO/2002/ 044137. June 2002.
100. Brendel J, Pirard B. Utilization of anthranilic acid amides as a medicament for treating arrhythmias and pharmaceutical preparations that contain said compounds. Aventis Pharma GMBH, assignee. Patent WO/2002/087568. November 2002.
101. Peukert S, Brendel J, Hemmerle H, et al. Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors. Aventis Pharma GMBH, assignee. Patent WO/2002/046162. June 2002.
102. Brendel J, Pirard B, Peukert S, et al. Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof. Aventis Pharma GMBH, assignee. Patent WO/2002/088073. November 2002.
103. Brendel J, Böhme T, Peukert S, et al. Anthranilic acid amides with a heteroarylsulfonyl side chain, and use thereof as antiarrhythmic active substances. Aventis Pharma GMBH, assignee. Patent WO/2002/100825. December 2002.
104. Peukert S, Brendel J, Hemmerle H, et al. Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect. Aventis Pharma GMBH, assignee. Patent WO/2002/048131. June 2002.
105. Brendel J, Schmidt W, Below P.2′-substituted 1,1′biphenyl-2- carbox-amides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them. Aventis Pharma GMBH, assignee. Patent US6531495. March 2003.
106. Brendel J, Schmidt W, Below P.2′-substituted 1,1′-biphenyl-2- carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds. Aventis Pharma GMBH, assignee. Patent WO/ 2001/025189. April 2001.
107. Wirth KJ, Brendel J, Gögelein H. Combination of phenylcarboxamides with β-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias. Sanofi-Aventis GMBH, assignee. Patent WO/2005/ 025674. March 2005.
108. Wirth KJ. Kv1.5-blocker for the selective increase of atrial contractility and treatment of cardiac insufficiency. Sanofi-Aventis GMBH, assignee. Patent WO/2005/084675. September 2005.
109. Fichman M, Chen D, Penland RC, et al. Thiotriazolyl derivatives. Epix Inc., assignee. Patent WO/2007/047394. April 2007.
110. Lloyd J, Finlay HJ, Vaccaro W, et al. Potassium channel inhibitors and method. Bristol-Meyers Squibb, assignee. Patent WO/2000/012077. March 2000.
111. Gross MF, Castle NA. Potassium channel inhibitors. Icagen Inc., assignee. Patent WO/1999/037607. July 1999.
112. Atwal KS, Vaccaro W, Lloyd J, et al. Heterocyclic dihydropyrimidines as potassium channel inhibitors. Bristol-Meyers Squibb, assignee. Patent WO/2001/040231. June 2001.
113. Castle NA, Gross MF, Mendoza JS. Potassium channel inhibitors. Icagen Inc., Eli Lilly and Company, assignees. Patent WO/1999/062891. December 1999.
114. Han W, Hu Z. Heterocyclic dihydropyrimidine compounds. Bristol-Meyers Squibb, assignee. Patent WO/2007/027454. March 2007.
115. Kur inhibitors. Bristol-Meyers Squibb, assignee. Patent WO/2007/030582. March 2007.
116. Lloyd J, Jeon YT, Finlay HJ, et al. Cycloalkyl inhibitors of potassium channel function. Bristol-Meyers Squibb, assignee. Patent WO/2003/ 063797. August 2003.
117. Lloyd J, Jeon YT, Finlay HJ, et al. Heterocyclo inhibitors of potassium channel function. Bristol-Meyers Squibb, assignee. Patent WO/2003/ 088908. October 2003.
118. Gross MF, Lloyd J; Piperidine derivatives as prodrugs of potassium channel inhibitors. Bristol-Meyers Squibb, assignee. Patent WO/2006/ 073967. July 2006.
119. Baker RK, Chee J, Bao J, et al. Carbocyclic potassium channel inhibitors. Merck & Co., assignee. Patent WO/2000/025770. May 2000.
120. Bao J, Kayser F, Kotliar A, et al. Heterocyclic potassium channel inhibitors. Merck & Co., assignee. Patent WO/2000/025786. May 2000.
121. Dinsmore CJ, Bergman JM, McIntyre CJ, et al. Isoquinolinone potassium channel inhibitors. Merck & Co., assignee. Patent WO/ 2005/030726. April 2005.
122. Issacs R, Dinsmore CJ, McIntyre CJ, et al. Isoquinolinone potassium channel inhibitors. Merck & Co., assignee. Patent WO/2005/030727. July 2005.
123. Trotter BW, Claiborne C, Ponticello GS, et al. Isoquinolinone potassium channel inhibitors. Merck & Co., assignee. Patent WO/2005/030791. April 2005.
124. Dinsmore CJ, Bergman JM, McIntyre CJ, et al. Isoquinolinone potassium channel inhibitors. Merck & Co., assignee. Patent WO/2005/ 046578. May 2005.
125. Baker RK, Kayser F, Bao J, et al. Benzamide potassium channel inhibitors. Merck & Co., assignee. Patent WO/2000/025774. May 2000.
126. Dinsmore CJ, Bergman JM. Quinoline potassium channel inhibitors. Merck & Co., assignee. Patent WO/2005/030792. April 2005.
127. Claremon DA, McIntyre CJ, Liverton NJ. Isoquinolinone potassium channel inhibitors. Merck & Co., assignee. Patent WO/2002/024655. March 2002.
128. Trotter BW, Nanda KK, Kett NR, et al. Isoquinoline potassium channel inhibitors. Merck & Co., assignee. Patent WO/2005/030130. April 2005.
129. Trotter BW, Nanda KK, Wolkenberg SE, et al. Potassium channel inhibitors. Merck & Co., assignee. Patent WO/2007/015775. February 2007.
130. Dinsmore CJ, Bergman JM. Quinoline potassium channel inhibitors. Merck & Co., assignee. Patent WO/2005/030129. April 2005.
131. Tanikawa K, Ohrai K, Sato M, et al. Chroman derivatives. Nissan Chemical Industries., assignee. Patent WO/1998/004542. February 1998.
132. Tanikawa K, Ohrai K, Yanagihara K, et al. Chroman derivatives. Nissan Chemical Industries., assignee. Patent WO/2000/058300. October 2000.
133. Tanikawa K, Ohrai K, Yanagihara K, et al. 4-oxybenzopyran derivative. Nissan Chemical Industries., assignee. Patent WO/ 2001/021609. March 2001.
134. Tanikawa K, Ohrai K, Yanagihara K, et al. Benzopyran derivative. Nissan Chemical Industries., assignee. Patent WO/2001/021610. March 2001.
135. Tanikawa K, Ohrai K, Yanagihara K, et al. 4-oxybenzopyran derivative. Nissan Chemical Industries., assignee. Patent WO/ 2001/025224. April 2001.
136. Ford J, Almer NJ, Atherall JF, et al. Thienopyrimidine derivatives as potassium channel inhibitors. Xention Discovery Ltd., assignee. Patent WO/2004/111057. December 2004.
137. Ford J, Palmer NJ, Atherall JF, et al. Furanopyrimidine compounds effective as potassium channel inhibitors. Xention Discovery Ltd., assignee. Patent WO/2005/121149. December 2005.
138. Ford J, Madge DJ, Palmer NJ, et al. Compounds. Xention Discovery Ltd., assignee. Patent WO/2006/061642. June 2006.
139. Ford J, Madge DJ, Payne HJ, et al. Thieno (3, 2-C) pyridine compounds. Xention Ltd., assignee. Patent WO/2007/066127. June 2007.
140. Peukert S, Brendel J, Pirard B, et al. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004;14:2823-2827.
141. Nattel S, Shiroshita-Takeshita A, Brundel BJ, et al. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis. 2005;48: 9-28.
142. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, et al. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006;69:865-875.